What is your approach to adjuvant chemotherapy for a postmenopausal woman with pT1cN0 grade 2 ER+ breast cancer (IDC) and OncoType RS of 25?

Since the Oncotype Dx recurrence score of 25 was the upper cut-off for randomization in the TAILORx trial, and since post-menopausal women with Oncotype Dx of 25 or less did not experience any benefit from chemotherapy, I would lean towards avoiding chemotherapy in this situation. However, I would d...

I would not administer chemotherapy to such a patient, based on results from TAILORx and RxPONDER - there is no likely benefit.